Kidney failure progression: doubling of SCr (mg/dL) · adults with early (stage 1 to 3) non‐diabetic CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Doubling of SCr · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Doubling of SCr Median · people with diabetes and kidney disease
It is very uncertain whether angiotensin‐converting‐enzyme inhibitors changes doubling of SCr Median compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Doubling of SCr Median · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in doubling of SCr Median compared with ACEi plus angiotensin receptor blockers (low certainty).
1 finding from 1 review
Doubling of SCr · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Doubling of SCr Median · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in doubling of SCr Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
Doubling of SCr Median · people with diabetes and kidney disease
Angiotensin receptor blockers (ARB) alone showed no clear difference in doubling of SCr Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).
1 finding from 1 review
Doubling of SCr · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Doubling of SCr · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Doubling of SCr4 · people with diabetes and kidney disease
Angiotensin receptor blocker (ARB) showed no clear difference in doubling of SCr4 compared with another ARB (low certainty).
1 finding from 1 review
Doubling of SCr Median · people with diabetes and kidney disease
Angiotensin receptor blockers may leads to lower doubling of SCr Median compared with placebo or no treatment (low certainty).
1 finding from 1 review